Aberrant activation of five embryonic stem cell-specific genes robustly predicts a high risk of relapse in breast cancers
- PMID: 37592220
- PMCID: PMC10436393
- DOI: 10.1186/s12864-023-09571-3
Aberrant activation of five embryonic stem cell-specific genes robustly predicts a high risk of relapse in breast cancers
Abstract
Background: In breast cancer, as in all cancers, genetic and epigenetic deregulations can result in out-of-context expressions of a set of normally silent tissue-specific genes. The activation of some of these genes in various cancers empowers tumours cells with new properties and drives enhanced proliferation and metastatic activity, leading to a poor survival prognosis.
Results: In this work, we undertook an unprecedented systematic and unbiased analysis of out-of-context activations of a specific set of tissue-specific genes from testis, placenta and embryonic stem cells, not expressed in normal breast tissue as a source of novel prognostic biomarkers. To this end, we combined a strict machine learning framework of transcriptomic data analysis, and successfully created a new robust tool, validated in several independent datasets, which is able to identify patients with a high risk of relapse. This unbiased approach allowed us to identify a panel of five biomarkers, DNMT3B, EXO1, MCM10, CENPF and CENPE, that are robustly and significantly associated with disease-free survival prognosis in breast cancer. Based on these findings, we created a new Gene Expression Classifier (GEC) that stratifies patients. Additionally, thanks to the identified GEC, we were able to paint the specific molecular portraits of the particularly aggressive tumours, which show characteristics of male germ cells, with a particular metabolic gene signature, associated with an enrichment in pro-metastatic and pro-proliferation gene expression.
Conclusions: The GEC classifier is able to reliably identify patients with a high risk of relapse at early stages of the disease. We especially recommend to use the GEC tool for patients with the luminal-A molecular subtype of breast cancer, generally considered of a favourable disease-free survival prognosis, to detect the fraction of patients undergoing a high risk of relapse.
Keywords: Breast cancer; Cancer/testis antigens; Ectopic expression; Prognosis biomarkers; Survival analysis.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10436393/bin/12864_2023_9571_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10436393/bin/12864_2023_9571_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10436393/bin/12864_2023_9571_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10436393/bin/12864_2023_9571_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10436393/bin/12864_2023_9571_Fig5_HTML.gif)
Similar articles
-
A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants.BMC Biol. 2021 Apr 12;19(1):70. doi: 10.1186/s12915-021-01002-7. BMC Biol. 2021. PMID: 33845831 Free PMC article.
-
NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.Clin Transl Med. 2024 Feb;14(2):e1554. doi: 10.1002/ctm2.1554. Clin Transl Med. 2024. PMID: 38344872 Free PMC article.
-
Systems biology comprehensive analysis on breast cancer for identification of key gene modules and genes associated with TNM-based clinical stages.Sci Rep. 2020 Jul 2;10(1):10816. doi: 10.1038/s41598-020-67643-w. Sci Rep. 2020. PMID: 32616754 Free PMC article.
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
-
Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.Front Endocrinol (Lausanne). 2023 Oct 12;14:1265520. doi: 10.3389/fendo.2023.1265520. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37900131 Free PMC article. Review.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous